Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 07:05 ET | Source: Curium

Curium receives marketing authorization in Switzerland for PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer

Swissmedic grants marketing authorization for PYLCLARI® in Switzerland b.e. Imaging is marketing authorization holder and has exclusive distribution rights for PYLCLARI® across Switzerland ZURICH,...
January 28, 2025 04:24 ET | Source: Curium

Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.
November 13, 2024 10:57 ET | Source: Curium

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
June 17, 2024 08:51 ET | Source: Curium

Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt

Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
June 17, 2024 08:51 ET | Source: Curium

Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
May 06, 2024 04:25 ET | Source: Curium

Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
May 06, 2024 04:25 ET | Source: Curium

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
April 09, 2024 08:50 ET | Source: Curium

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE